Lymperaki Evgenia, Kazeli Konstantina, Variti Georgia, Gerothanasi Magda, Gkinoudis Argyrios, Tsamesidis Ioannis, Vagdatli Eleni
Department of Biomedical Sciences, International Hellenic University, 57400 Thessaloniki, Greece.
Center for Interdisciplinary Research and Innovation (CIRI-AUTH), 57001 Thessaloniki, Greece.
Medicines (Basel). 2022 Jun 15;9(6):36. doi: 10.3390/medicines9060036.
COVID-19 disease is still a major global concern because of its morbidity and its mortality in severe disease. Certain biomarkers including Reactive Oxygen Species (ROS), vitamins, and trace elements are known to play a crucial role in the pathophysiology of the disease. The aim of our study was to evaluate how certain biomarkers, such as ROS, biochemical indicators, trace elements in serum blood of 139 COVID-19 hospitalized patients, and 60 non-COVID cases according to age and sex variations, can serve as the predictors for prognosis of COVID-19 outcome. An attempt of correlating these biomarkers with the severity of the disease as well as with each other is represented. All subjects were hospitalized from April 2021 until June 2021. A statistically significant increase of B12 levels (p = 0.0029) and ROS levels (p < 0.0001) as well as a decrease in albumin and Total Protein (T.P.) levels (p < 0.001) was observed especially in the early stage of the disease before CRP and ferritin elevation. Additionally, a statistically significant increase in ferritin (p = 0.007), B12 (p = 0.035, sALT p = 0.069, Glucose p = 0.012 and urea p = 0.096 and a decrease in Ca p = 0.005, T.P p = 0.052 albumin p = 0.046 between stage B (CRP values 6−30 mg/L) and C (CRP values 30−100 mg/L) was evident. Thus, this study concludes that clinicians could successfully employ biomarkers such as vitamin B12, ROS and albumin as possible prognosis tools for an early diagnosis. In addition, the total biochemical profile can assist in the understanding of the severity of COVID-19 disease, and could potentially lead to a better diet or early pharmaceutical treatment to prevent some of the more acute symptoms.
由于COVID-19疾病的发病率及其在重症中的死亡率，它仍然是全球主要关注的问题。已知某些生物标志物，包括活性氧（ROS）、维生素和微量元素，在该疾病的病理生理学中起着关键作用。我们研究的目的是评估某些生物标志物，如139例COVID-19住院患者以及60例非COVID病例血清中的ROS、生化指标、微量元素，如何根据年龄和性别差异作为COVID-19预后的预测指标。本文尝试将这些生物标志物与疾病严重程度以及它们之间的相互关系进行关联。所有受试者于2021年4月至2021年6月住院。观察到特别是在疾病早期，在CRP和铁蛋白升高之前，B12水平（p = 0.0029）和ROS水平（p < 0.0001）有统计学显著升高，而白蛋白和总蛋白（T.P.）水平降低（p < 0.001）。此外，在B期（CRP值6 - 30 mg/L）和C期（CRP值30 - 100 mg/L）之间，铁蛋白（p = 0.007）、B12（p = 0.035）、sALT（p = 0.069）、葡萄糖（p = 0.012）和尿素（p = 0.096）有统计学显著升高，而钙（p = 0.005）、T.P（p = 0.052）、白蛋白（p = 0.046）降低。因此，本研究得出结论，临床医生可以成功地将维生素B12、ROS和白蛋白等生物标志物作为早期诊断的可能预后工具。此外，整体生化指标有助于了解COVID-19疾病的严重程度，并可能有助于采取更好的饮食或早期药物治疗以预防一些更急性的症状。
